Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 08/10/2004, Updated: 07/18/2007) - In this trial, researchers are trying to determine whether a new chemotherapy agent called 17-DMAG will help prevent cancer cells from growing in patients with solid tumors or lymphomas. The agent inhibits a protein called HSP-90 that is found more often in cancer cells than in normal cells.
Immunotherapy for Nonresponsive Solid Tumors
(Posted: 07/20/2004, Updated: 07/18/2007) - In this phase I trial, researchers are testing the ability of interleukin-7 (IL-7) to stimulate patients' white blood cells to kill cancer cells in solid tumors that have not responded to standard therapies.
Biological Therapy for Advanced Kidney Cancer or Melanoma
(Posted: 07/10/2007) - This phase I clinical trial will assess the safety and tolerability of a new biological agent called GC1008 in patients with advanced kidney cancer or melanoma.
Comparing Radiation Therapies for Prostate Cancer
(Posted: 06/26/2007) - In this trial, men with favorable-risk, localized prostate cancer will be randomly assigned to receive conventionally fractionated radiation therapy over the course of about eight weeks (41 daily treatments) or hypofractionated radiotherapy over a five-and-a-half week period (28 daily treatments).
The Modafinil and Fatigue Trial
(Posted: 01/06/2004, Updated: 06/04/2007) - This study is testing the ability of modafinil to reduce fatigue in cancer patients who are receiving chemotherapy. The study will also examine the relationship between depression and fatigue in patients treated with modafinil.